The quality and safety of Fresenius Kabi's products (medicinal products, nutritional products, medical devices), services and therapies are of paramount importance.
Our interactions with patients using our products do not end with the supply of products or the provision of services but involve the monitoring and analysis of applicability, effectiveness and safety for patients of our products on the market. The gained insights are the basis for identifying opportunities for continuous improvement of products and services. Fresenius Kabi, therefore, monitors and evaluates relevant information and feedback on the products, services and therapies during its use and where necessary reports these to health authorities.
The monitoring of adverse reactions or events (side effects) associated with the use of medicinal products is referred to as pharmacovigilance (drug safety). The statutory pharmacovigilance commitments relate to our medicinal products for human use. Similar regulations exist for medical devices.
With the help of our vigilance activities, Fresenius Kabi ensures that the safety of its products is in line with regulatory requirements, and that the company is enabled to identify any changes in the benefit risk ratio at an early stage and react in a timely manner.